CAPLYTA (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study – Johnson & Johnson
Johnson & Johnson announced positive topline results from the pivotal Phase 3 study evaluating CAPLYTA (lumateperone) for the treatment of manic episodes with or without mixed features in… read more.
